Tue. 9 Apr 2024, 8:51am ET
Benzinga
Biotech, News, General
- NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field
- Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSense
- Lonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of work